{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T14:08:53Z","timestamp":1771164533031,"version":"3.50.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,15]]},"DOI":"10.7759\/cureus.103648","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T13:58:16Z","timestamp":1771163896000},"source":"Crossref","is-referenced-by-count":0,"title":["Marked Clinical and Functional Response to Tezepelumab After Failure of Anti-Interleukin-5 (Anti-IL-5) Therapy in Severe Asthma"],"prefix":"10.7759","author":[{"given":"Makoto","family":"Fujimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyoshi","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Sakaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2024.11.015","article-title":"Molecular mechanisms and clinical impact of biologic therapies in severe asthma","volume":"63","author":"Tashiro H","year":"2025","unstructured":"Tashiro H, Kuwahara Y, Kurihara Y, Takahashi K. Molecular mechanisms and clinical impact of biologic therapies in severe asthma. Respir Investig. 2025, 63:50-60. 10.1016\/j.resinv.2024.11.015","journal-title":"Respir Investig"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2022.11.006","article-title":"Current summary of clinical studies on anti-TSLP antibody, tezepelumab, in asthma","volume":"72","author":"Kurihara M","year":"2023","unstructured":"Kurihara M, Kabata H, Irie M, Fukunaga K. Current summary of clinical studies on anti-TSLP antibody, tezepelumab, in asthma. Allergol Int. 2023, 72:24-30. 10.1016\/j.alit.2022.11.006","journal-title":"Allergol Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2025.04.022","article-title":"Switching to tezepelumab from other biologics in patients with severe asthma: a retrospective study","volume":"63","author":"Sumi T","year":"2025","unstructured":"Sumi T, Ishigooka T, Matsuura K, et al.. Switching to tezepelumab from other biologics in patients with severe asthma: a retrospective study. Respir Investig. 2025, 63:592-9. 10.1016\/j.resinv.2025.04.022","journal-title":"Respir Investig"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1655919","article-title":"Cold temperature enhances innate eosinophilic airway inflammation via transient receptor potential ankyrin1","volume":"16","author":"Dotake Y","year":"2025","unstructured":"Dotake Y, Matsuyama T, Machida K, et al.. Cold temperature enhances innate eosinophilic airway inflammation via transient receptor potential ankyrin1. Front Immunol. 2025, 16:1655919. 10.3389\/fimmu.2025.1655919","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis V","year":"2002","unstructured":"Soumelis V, Reche PA, Kanzler H, et al.. Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP. Nat Immunol. 2002, 3:673-80. 10.1038\/ni805","journal-title":"Nat Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/458877-marked-clinical-and-functional-response-to-tezepelumab-after-failure-of-anti-interleukin-5-anti-il-5-therapy-in-severe-asthma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T13:58:17Z","timestamp":1771163897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/458877-marked-clinical-and-functional-response-to-tezepelumab-after-failure-of-anti-interleukin-5-anti-il-5-therapy-in-severe-asthma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":5,"URL":"https:\/\/doi.org\/10.7759\/cureus.103648","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,15]]}}}